Natalie Kay Brown

Natalie Kay Brown

Auto-generated profile, based on publicly available information

Natalie Kay Brown

Islet Cell and Regenerative Biology, Joslin Diabetes Center, Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2019 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
DJDario F. De Jesus
Dario F. De Jesus
ZZZijie Zhang
Zijie Zhang
SKSevim Kahraman
Sevim Kahraman
NBNatalie K. Brown
Natalie K. Brown
MCMengjie Chen
Mengjie Chen
RKROHIT kULKARNI
ROHIT kULKARNI

1 January 2019 in Advanced Drug Delivery Reviews
Verified
Journal Article
Closed access
AEAlexander U. Ernst
Alexander U. Ernst
DBDaniel T. Bowers
Daniel T. Bowers
LWLong-Hai Wang
Long-Hai Wang
KSKaavian Shariati
Kaavian Shariati
MPMitchell D. Plesser
Mitchell D. Plesser
MMMinglin Ma
Minglin Ma

14 July 2021 in Advanced Science
Verified
Journal Article
Open access
XWXi Wang
Xi Wang
NBNatalie K. Brown
Natalie K. Brown
BWBo Wang
Bo Wang
KSKaavian Shariati
Kaavian Shariati
KWKai Wang
Kai Wang
MMMinglin Ma
Minglin Ma
Islet transplantation has shown promise as a curative therapy for type 1 diabetes (T1D). However, the side effects of systemic immunosuppression and limited long‐term viability of engrafted islets, together with the scarcity of donor organs, highlight an urgent need for the development of new, improved, and safer cell‐replacement strategies. Induction of local immunotolerance to prevent allo‐rejection against islets and stem cell derived β cells has the potential to improve graft function and broaden the applicability of cellular therapy while minimizing adverse effects of systemic immunosuppression. In this mini review, recent developments in non‐encapsulation, local immunomodulatory approaches for T1D cell replacement therapies, including islet/β cell modification, immunomodulatory biomaterial platforms, and co‐transplantation of immunomodulatory cells are discussed. Key advantages and remaining challenges in translating such technologies to clinical settings are identified. Although many of the studies discussed are preliminary, the growing interest in the field has led to the exploration of new combinatorial strategies involving cellular engineering, immunotherapy, and novel biomaterials. Such interdisciplinary research will undoubtedly accelerate the development of therapies that can benefit the whole T1D population.

23 March 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DJDario F. De Jesus
Dario F. De Jesus
KOKazuki Orime
Kazuki Orime
DKDorota Kaminska
Dorota Kaminska
TKTomohiko Kimura
Tomohiko Kimura
GBGiorgio Basile
Giorgio Basile
RKROHIT kULKARNI
ROHIT kULKARNI
The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. Although gene-environment interactions have been implicated in the etiology of several disorders, the impact of paternal and/or maternal metabolic syndrome on the clinical phenotypes of offspring and the underlying genetic and epigenetic contributors of NAFLD have not been fully explored. To this end, we used the liver-specific insulin receptor knockout (LIRKO) mouse, a unique nondietary model manifesting 3 hallmarks that confer high risk for the development of NAFLD: hyperglycemia, insulin resistance, and dyslipidemia. We report that parental metabolic syndrome epigenetically reprograms members of the TGF-β pathway, including neuronal regeneration–related protein (NREP) and growth differentiation factor 15 (GDF15). NREP and GDF15 modulate the expression of several genes involved in the regulation of hepatic lipid metabolism. In particular, NREP downregulation increases the protein abundance of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP-citrate lyase (ACLY) in a TGF-β receptor/PI3K/protein kinase B–dependent manner, to regulate hepatic acetyl-CoA and cholesterol synthesis. Reduced hepatic expression of NREP in patients with NAFLD and substantial correlations between low serum NREP levels and the presence of steatosis and nonalcoholic steatohepatitis highlight the clinical translational relevance of our findings in the context of recent preclinical trials implicating ACLY in NAFLD progression.

25 September 2024 in The EMBO Journal
Verified
Journal Article
Open access
SKSevim Kahraman
Sevim Kahraman
DJDario F De Jesus
Dario F De Jesus
JWJiangbo Wei
Jiangbo Wei
NBNatalie K Brown
Natalie K Brown
ZZZhongyu Zou
Zhongyu Zou
RKROHIT kULKARNI
ROHIT kULKARNI
N 6 -methyladenosine (m 6 A) is the most abundant chemical modification in mRNA and plays important roles in human and mouse embryonic stem cell pluripotency, maintenance, and differentiation. We have recently reported that m 6 A is involved in the postnatal control of β-cell function in physiological states and in type 1 and 2 diabetes. However, the precise mechanisms by which m 6 A acts to regulate the development of human and mouse pancreas are unexplored. Here, we show that the m 6 A landscape is dynamic during human pancreas development, and that METTL14, one of the m 6 A writer complex proteins, is essential for the early differentiation of both human and mouse pancreatic cells.

18 September 2026 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
DJDario F. De Jesus
Dario F. De Jesus
NBNatalie K. Brown
Natalie K. Brown
GFGarrett Fogarty
Garrett Fogarty
GGGuilherme Gabriel
Guilherme Gabriel
SWShirong Wang
Shirong Wang
RKROHIT kULKARNI
ROHIT kULKARNI
Pancreatic α-cells are central regulators of glucose and amino acid homeostasis, yet the mechanisms that preserve α-cell identity and function remain incompletely understood. N6-methyladenosine (m6A) is a widespread mRNA modification that is essential for β-cell biology and pancreatic endocrine differentiation. Here we show that m6A is a key regulator of α-cell function and plasticity. In α-cells, metabolic cues that stimulate glucagon secretion such as L-arginine increase METTL3, METTL14 and m6A levels. Loss of m6A impairs amino acid-stimulated glucagon secretion, disrupts α-cell identity programmes and induces metabolic rewiring. In mice, α-cell-specific Mettl14 deletion reduces α-cell mass, increases β-cell mass and promotes α-to-β-cell conversion, accompanied by the emergence of late β-like states with features of incomplete maturation. Mechanistically, m6A-eCLIP identifies Yy1 as a direct m6A-sensitive target, and elevated YY1 links m6A loss to signalling rewiring and erosion of α-cell identity. These findings identify m6A as a central regulator of α-cell state and reveal an epitranscriptomic mechanism controlling endocrine cell plasticity.